Medium-term plans, capital spending, new plants, products and drug approvals from Japanese companies.
Quantum Solutions has signed a ¥9.51bn contract for its first GPU server order for an Osaka data center, but only about ¥1.3bn is self-funded; the rest depends on an unfinished shareholder loan and customer prepayment arrangement, and the supplier can walk away if Japanese regulators force disclosure of its identity.
Nippon Paper is closing its wholly owned Hungarian subsidiary that makes a lithium-ion battery chemical, booking a roughly ¥5bn impairment as it blames shifting European and US EV subsidies and rules for killing the plant's economics after local production began in 2025.
Star Seeds' server-resale subsidiary will book about $42.9mn (¥6.7bn) from a second data-center hardware sale to Taiwan's Inventec Corporation, at least a tenth of prior-year group revenue, but pricing details stay confidential and the sale is already baked into existing guidance.
METI has selected TIER IV as an indirect recipient of a subsidy covering two-thirds of a requested ¥6.0bn budget to adapt its Autoware software for autonomous buses in Saudi Arabia, but the formal grant decision and final amount are still pending.
METI has approved a revised wheeling-charge revenue forecast for Shikoku Electric Power Transmission & Distribution, with new unit prices due from November 2026, but the parent still hasn't decided whether the revision will reach retail electricity bills.
China's NMPA cleared the self-injected, once-weekly formulation of Leqembi as first-line therapy, the second market after the US to allow at-home dosing for a disease that has mostly meant fortnightly hospital infusions.
Yamato Holdings will shut the dedicated domestic cargo-plane operation it built with Japan Airlines by around June 2027, after yen weakness and fuel costs pushed air-transport costs up faster than trucking, widening the price gap between the two modes beyond what the company had assumed when it launched the service in 2024.
Japan's health ministry listed Cuorips' heart-failure therapy ReHeart at ¥53.2mn per treatment for patients who have exhausted standard drug and invasive care, using the cost-calculation pricing method under the new-technology category.
Astroscale's Japanese unit has signed Isar Aerospace to launch ADRAS-J2, a mission to capture and deorbit a three-tonne rocket stage around the year to April 2028, and the ¥12bn contract was already assumed in the group's earnings guidance, so it adds nothing new to the numbers.
Honda and Nissan have signed a binding contract to make the core ECUs, operating system, middleware and control software in their next-generation vehicles common to both companies, targeting deployment from fiscal 2029 with no synergy figure disclosed and only a minor financial impact flagged for the year to March 2027.
Takeuchi Mfg says a construction-labor shortage pushed its new factory's opening from January 2028 to May 2029, and rising building costs plus spec changes lifted the project's budget from about ¥18.0bn to about ¥24.6bn, with output capacity unchanged.
Enshu Limited will halt production at its Thai manufacturing subsidiary, BANGKOK ENSHU MACHINERY, by the end of September, after the EV transition and Chinese automaker growth cut Japanese capital spending in Thailand and left the factory underused; the Thai sales unit stays open, and machine production moves to the company's Japan and China bases.
Star Flyer will pay about ¥3.3bn over ten years for a single spare LEAP-1A26 engine starting December 2027, telling the exchange that a global engine shortage has made short-notice replacements hard to find.
Nippon Shokubai now expects to spend about ¥43.0bn, up from ¥37.5bn, on its Kitakyushu LiFSI plant and to start commercial output in December 2028 instead of July 2028, citing delayed land purchase and higher copper, petroleum and construction costs, while the government's ¥12.5bn subsidy commitment holds steady.
Kioxia and SanDisk say they will invest roughly ¥5tn, more than $31bn, in Japanese flash-memory production by 2032 at two existing plants, but the plan is explicitly conditional on support from the Japanese government that has not yet been detailed.
Yamabiko is chasing more than 20% annual growth in robotic lawn mower sales, nearly double the roughly 13% pace it forecasts for the professional segment, leaning on a Toro Company partnership and golf-course automation while a strong quarter funds the bet.
FDA acceptance of a Phase 2 filing for an Alzheimer's cognition drug licensed from Nxera Pharma triggers a $10mn payment, about ¥1.59bn, that the company will book as third-quarter revenue under a fiscal year that already assumed it.
enish's board has approved a ¥100mn Solana purchase, the first slice of a ¥640mn treasury plan, and will now run quarterly mark-to-market gains and losses on the holding directly through earnings.
Kuraudia Holdings is shutting its 30-year-old Qingdao wedding-dress plant over rising Chinese labor costs and an aging workforce, booking roughly ¥170mn in restructuring charges while making its Ho Chi Minh City subsidiary the primary production site.
Terra Drone was the only company to pass Japan's interceptor-drone demonstration test, its Terra B1 model chosen from four finalists narrowed out of 38 initial bidders, and the defense agency is targeting a mass-production contract by late August, while Terra Drone says the earnings impact is still under review.
138 employees at SAXA and its service subsidiary accepted the electronics maker's early-retirement offer, overshooting a 120-person target, and the company has already booked a ¥1.269bn charge for the extra severance and outplacement costs, with the overflow bill still being worked out.
GENDA will expand exclusive Sanrio character prizes at its domestic GiGO arcades and jointly run promotions and store openings across roughly 13,000 North American amusement sites, though the company says the near-term earnings impact is minor.
Oncolys BioPharma began commercial sales of its OBP-301 oncolytic virus therapy on August 21, about two and a half months after Japan's health ministry approved it for esophageal cancer patients who cannot have curative surgery or chemoradiotherapy, with Fujifilm Toyama Chemical distributing it to hospitals.
Marumae now targets ¥8.2bn in operating profit for the year to August 2028, up from ¥5.6bn, after semiconductor equipment orders and price increases outran its earlier medium-term plan, with vacuum-chamber demand at subsidiary KMAC doing much of the work.